Home / Brands / Zyvex / Zyvex Pharmaceuticals Retatrutide 20 mg Research Peptide Vial

Zyvex Pharmaceuticals

Zyvex Pharmaceuticals Retatrutide 20 mg Research Peptide Vial

Name: Zyvex Pharmaceuticals Retatrutide 20 mg Research Peptide Vial
Brand: Zyvex Pharmaceuticals
SKU: OFFER-8503
Availability: OutOfStock

Injection · 20 mg · vial

Out of stock

Zyvex Pharmaceuticals Retatrutide is a triple receptor agonist peptide in a 20 mg lyophilized vial, studied for its combined GLP-1, GIP and glucagon activity in laboratory and clinical research rather than sold as a licensed medicine. Available for purchase as Retatrutide 20 mg.

GMP-manufactured, HPLC-verified with the Certificate of Analysis on file. Retatrutide for sale with international shipping in a 4 to 10 day transit window.

Discreet plain packaging

Worldwide reship guarantee

Crypto & card accepted

Product overview

Zyvex Pharmaceuticals Retatrutide 20 mg - A Triple Incretin Agonist

Zyvex Pharmaceuticals Retatrutide is a 20 mg lyophilized vial of a peptide that acts on three receptors at once: GLP-1, GIP and glucagon. The fact file for this card describes the compound as a next-generation incretin analogue in which the third, glucagon arm is the difference from the dual agonists, and it records no precise published half-life, only that manufacturer material and reviews describe a profile that supports one subcutaneous injection per week. Treat the vial as laboratory material for research use.

One 20 mg lyophilized vial of the triple agonist peptide
GMP-manufactured - pharmaceutical-grade production standards
HPLC-verified - independent lab testing with COA per batch
international shipping with a 4 to 10 day transit window

How Retatrutide Works

GLP-1 and GIP are incretin hormones released after a meal, and adding a glucagon agonist changes energy expenditure rather than only appetite signalling, which is the mechanism the research literature describes. The fact file contains no human dose for this vial, so the only firm statement is receptor activity, not schedule. Within the catalogue the closest comparisons are the single-agonist Semaglutide pens, the dual agonist Tirzepatide vials and this brand's own Zyvex Semaglutide 10 mg.

Reconstitution & Storage

Add bacteriostatic water down the inside wall of the vial and swirl, do not shake, because the peptide foams and loses material. Divide the milligrams on the label by the millilitres added to read mg per ml: 20 mg with 2 ml gives 10 mg/ml, which is a measuring instruction for laboratory work and not a human dose, since none has been validated. Keep the sealed powder cold and dark, and the mixed solution refrigerated rather than frozen.

Quality & Authenticity

Each batch is produced under GMP conditions and checked by HPLC, with the Certificate of Analysis held for the batch so the vial can be traced to its lot. Purchase retatrutide here as a 20 mg research vial, and note that it is not an approved medicine in any market.

For laboratory research only. Consult a healthcare professional before use.

Specifications

Brand	Zyvex Pharmaceuticals
Active Substance	Retatrutide, triple incretin agonist peptide
Dosage	20 mg per vial
Package	1 lyophilized vial
Form	Lyophilized powder, requiring reconstitution
Drug Class	Research peptide, no approved human indication
Manufacturing	GMP-certified
Testing	HPLC per batch, COA on file
Shipping	International, 4-10 days transit

Stacks

Retatrutide Beside Semaglutide

Laboratory notes on incretin research usually place the single agonist Zyvex Semaglutide next to the triple agonist, because the difference in receptor count is the whole point of the comparison.

Outcome: two data sets with different receptor coverage, so results are not interchangeable.

Note: neither vial carries a validated human dosing schedule.

A 20 mg Reconstitution Plan

One 20 mg vial with 2 ml of bacteriostatic water gives 10 mg/ml, and with 4 ml it gives 5 mg/ml, which keeps the arithmetic easy when small aliquots are drawn.

Outcome: a round concentration figure reduces measuring error in the laboratory.

FAQ

Before you ask

Questions, answered

It is a 20 mg lyophilized vial of retatrutide, a peptide that acts as an agonist at the GLP-1, GIP and glucagon receptors at the same time. The fact file for this card describes it as a next-generation incretin analogue, and the third glucagon arm is what separates it from the dual agonists. It is supplied as research material and is not an approved medicine.

The checked sources contain no precise published half-life figure, and this card does not invent one. What they do record is a description in manufacturer material and review articles that the profile allows one subcutaneous injection per week, which is a schedule statement rather than a measured elimination value. Treat any specific half-life quoted elsewhere as unconfirmed until a primary source can be cited.

Let bacteriostatic water run down the inside wall of the vial and swirl it gently, never shake, because the peptide foams and foam costs you material. Then divide the milligrams by the millilitres: 20 mg with 2 ml gives 10 mg/ml and with 4 ml gives 5 mg/ml. Keep the powder cold and dark before mixing and the solution refrigerated afterwards.

The fact file records liver toxicity as low and notes that GLP-1 class drugs sit under monitoring rather than prohibition, and no WADA listing for the peptide form was found in the sources checked. Those are statements about the files, not a safety verdict, and no detection window for this peptide is established. Human safety data belongs with a clinician, not with a research vial.

The 20 mg vial is listed on this page as research material, with the pack selected above. At the last check it was out of stock and no price was printed for the offer, and international shipping is listed at 45.00 USD with handling of one to two days and a four to ten day transit window.

No reviews yet

Be the first to share your experience with Zyvex Pharmaceuticals Retatrutide 20 mg Research Peptide Vial

Complete the cycle